타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap) Regeneron / Bayer·VEGF-A / VEGF-B / PIGF 244 trials | |||
|---|---|---|---|---|
Overview Program | Avastin (bevacizumab) | Eylea (aflibercept) | Lucentis (ranibizumab) | Vabysmo (faricimab) |
Overview Company | Roche / Genentech | Regeneron / Bayer | Roche / Genentech | Roche / Genentech |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | VEGF-A | VEGF-A / VEGF-B / PIGF | VEGF-A | Ang-2 / VEGF-A |
Overview Indication | US label: colorectal, non-squamous NSCLC, glioblastoma, renal, cervical and ovarian cancers; regimen-specific indications | Wet AMD, DME, RVO, diabetic retinopathy | Wet AMD, DME, RVO, myopic CNV | Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | novel NaPi2b-targeting ADC YL205 in heavily pretreated platinum-resistant ovarian cancer | unique records | Novel metrics that included Visual Acuity Recovery Rate (VARR), Time to 1 | Dual pathway blockade targets vascular instability, not just leakage, which is what supports extended intervals. |
Positioning Known limitation | downregulation across different drug combinations | Tachyphylaxis, fibrosis, and need for shorter dosing intervals in subset of patients. | Anatomic non-response and fibrotic disease; switch/combination with other anti-VEGF agents. | Persistent fluid despite dual blockade; interval shortening in a subset of eyes. |
Positioning Development positioning | — | — | — | 1L anti-VEGF alternative |
MoA Mechanism | target proteins (DHFR, TGF-1beta, estrogen receptor | Aflibercept acts as a soluble decoy receptor binding VEGF-A, VEGF-B, and PlGF with higher affinity than native VEGFR, preventing activation of VEGFR1/2 and reducing pathological angiogenesis and vascular permeability in the retina. | Ranibizumab is a humanized Fab fragment that binds all isoforms of VEGF-A, preventing VEGFR activation and reducing neovascularization and retinal edema. | Neutralizes VEGF-A to reduce neovascularization and permeability while blocking Ang-2 to restore Tie2 signaling and vascular stability, reducing inflammation-driven leakage. |
MoA Biomarker | biomarker angiopoietin-2 (Ang-2), producing effects similar to the Wnt/β-catenin inhibitor (dickkopf-re | biomarkers can reliably diagnose and monitor PCV, restricting the role of invasive indocyanine green angiogra | biomarker of treatment response, supporting further validation in larger independent cohorts | OCT central subfield thickness, BCVA, presence of intraretinal fluid. |
Toxicology Species | — | Cynomolgus monkey | — | — |
Toxicology Animal (cat.) | — | NHP | — | — |
Toxicology Major finding | — | Conjunctival hemorrhage, eye pain, cataract, vitreous detachment; endophthalmitis risk with injection procedure. | Intraocular inflammation, retinal detachment, arterial thromboembolic events (low incidence). | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. |
Toxicology CRS | — | N/A | N/A | N/A |
Clinical Safety signal | — | Conjunctival hemorrhage, eye pain, cataract, vitreous detachment; endophthalmitis risk with injection procedure. | Intraocular inflammation, retinal detachment, arterial thromboembolic events (low incidence). | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Preclinical Animal (cat.) | — | — | — | Rat |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap) Regeneron / Bayer·VEGF-A / VEGF-B / PIGF 244 trials | |||
|---|---|---|---|---|
Overview Program | Avastin (bevacizumab) | Eylea (aflibercept) | Lucentis (ranibizumab) | Vabysmo (faricimab) |
Overview Company | Roche / Genentech | Regeneron / Bayer | Roche / Genentech | Roche / Genentech |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | VEGF-A | VEGF-A / VEGF-B / PIGF | VEGF-A | Ang-2 / VEGF-A |
Overview Indication | US label: colorectal, non-squamous NSCLC, glioblastoma, renal, cervical and ovarian cancers; regimen-specific indications | Wet AMD, DME, RVO, diabetic retinopathy | Wet AMD, DME, RVO, myopic CNV | Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | novel NaPi2b-targeting ADC YL205 in heavily pretreated platinum-resistant ovarian cancer | unique records | Novel metrics that included Visual Acuity Recovery Rate (VARR), Time to 1 | Dual pathway blockade targets vascular instability, not just leakage, which is what supports extended intervals. |
Positioning Known limitation | downregulation across different drug combinations | Tachyphylaxis, fibrosis, and need for shorter dosing intervals in subset of patients. | Anatomic non-response and fibrotic disease; switch/combination with other anti-VEGF agents. | Persistent fluid despite dual blockade; interval shortening in a subset of eyes. |
Positioning Development positioning | — | — | — | 1L anti-VEGF alternative |
MoA Mechanism | target proteins (DHFR, TGF-1beta, estrogen receptor | Aflibercept acts as a soluble decoy receptor binding VEGF-A, VEGF-B, and PlGF with higher affinity than native VEGFR, preventing activation of VEGFR1/2 and reducing pathological angiogenesis and vascular permeability in the retina. | Ranibizumab is a humanized Fab fragment that binds all isoforms of VEGF-A, preventing VEGFR activation and reducing neovascularization and retinal edema. | Neutralizes VEGF-A to reduce neovascularization and permeability while blocking Ang-2 to restore Tie2 signaling and vascular stability, reducing inflammation-driven leakage. |
MoA Biomarker | biomarker angiopoietin-2 (Ang-2), producing effects similar to the Wnt/β-catenin inhibitor (dickkopf-re | biomarkers can reliably diagnose and monitor PCV, restricting the role of invasive indocyanine green angiogra | biomarker of treatment response, supporting further validation in larger independent cohorts | OCT central subfield thickness, BCVA, presence of intraretinal fluid. |
Toxicology Species | — | Cynomolgus monkey | — | — |
Toxicology Animal (cat.) | — | NHP | — | — |
Toxicology Major finding | — | Conjunctival hemorrhage, eye pain, cataract, vitreous detachment; endophthalmitis risk with injection procedure. | Intraocular inflammation, retinal detachment, arterial thromboembolic events (low incidence). | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. |
Toxicology CRS | — | N/A | N/A | N/A |
Clinical Safety signal | — | Conjunctival hemorrhage, eye pain, cataract, vitreous detachment; endophthalmitis risk with injection procedure. | Intraocular inflammation, retinal detachment, arterial thromboembolic events (low incidence). | Injection-procedure risks — endophthalmitis, retinal detachment, IOP elevation — plus intraocular inflammation. Conjunctival hemorrhage is the most common local event. |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Preclinical Animal (cat.) | — | — | — | Rat |
추천 비교
추천 비교